SPY389.81+9.45 2.48%
DIA315.83+6.38 2.06%
IXIC13,575.98+383.63 2.91%

DJ FDA Schedules Advisory Committee For J&J's COVID-19 Vaccine Candidate For Feb. 26 -- MarketWatch

· 02/05/2021 07:31
For more from MarketWatch: http://www.marketwatch.com/newsviewer

A Food and Drug Administration advisory committee is now scheduled to meet Feb. 26 for an all-day meeting to discuss Johnson & Johnson's (JNJ) COVID-19 vaccine candidate. This is the next step in the regulatory process after J&J said Thursday it has submitted an application (http://www.marketwatch.com/story/jj-submits-application-for-its-covid-19-shot-to-the-fda-2021-02-04%7CNEW) for its experimental vaccine to the FDA. Members of the Vaccines and Related Biological Products Advisory Committee will discuss and then vote on whether the benefits of the single-dose vaccine outweigh the risks. The FDA then takes the committee's recommendation into account as it decides whether or not to authorize the J&J shot. The advisory committee also held meetings to discuss the COVID-19 vaccines developed by BioNTech SE (BNTX)/Pfizer Inc. (PFE) and Moderna Inc. (MRNA). Both vaccines were recommended by the committee, and emergency authorizations were granted by the FDA within days of those meetings. J&J's stock has gained 5.2% over the past 12 months, while the broader S&P 500 is up 17.4%.

-Jaimy Lee

(END) Dow Jones Newswires

February 05, 2021 07:31 ET (12:31 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.